World's Best Scientists 2026 revealed!
Award Badge
Medicine
Korea
2026

D-Index & Metrics

Medicine

D-Index
108
Citations
77377
World Ranking
5862
National Ranking
8

Research.com Recognitions

  • 2026 - Research.com Medicine in Korea Leader Award
  • 2025 - Research.com Medicine in Korea Leader Award

Overview

Seock-Ah Im is affiliated with Seoul National University Hospital in South Korea. Their research primarily focuses on medicine, with a substantial number of publications in oncology and related biomedical fields. They have contributed extensively to the understanding and treatment of advanced breast cancer and molecular mechanisms underlying various cancers.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Their research spans multiple subfields such as:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Genetics
  • Molecular Biology

Main topics covered in their work involve:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • PARP inhibition in cancer therapy
  • Cancer-related Molecular Pathways

Seock-Ah Im has published in the following venues most frequently:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research and Treatment
  • Annals of Oncology

Significant recent papers by Seock-Ah Im include:

  • Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, 2022, New England Journal of Medicine
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, 2020, The Lancet
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology
  • Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer, 2022, New England Journal of Medicine
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, 2020, The Lancet Oncology

Frequent coauthors collaborating with Seock-Ah Im include:

  • Kyung-Hun Lee
  • Joohyuk Sohn
  • Yeon Hee Park
  • Javier Cortés
  • Sung-Bae Kim

Best Publications

  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Peter Schmid;Stephen Y Chui;Leisha A Emens

  • Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    José Baselga;Javier Cortés;Sung-Bae Kim;Seock-Ah Im

  • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu

  • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Laslo Roman

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

    Norikazu Masuda;Soo-Jung Lee;Shoichiro Ohtani;Young-Hyuck Im

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Shanu Modi;Cristina Saura;Toshinari Yamashita;Yeon Hee Park

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Debu Tripathy;Seock Ah Im;Marco Colleoni;Fabio Franke

  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Seock-Ah Im;Yen-Shen Lu;Aditya Bardia;Nadia Harbeck

  • 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Ling Ming Tseng

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero

Frequent Co-Authors

Yung-Jue Bang
Yung-Jue Bang Seoul National University
Dae Seog Heo
Dae Seog Heo Seoul National University Hospital
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Dong-Young Noh
Dong-Young Noh Seoul National University
Sung-Bae Kim
Sung-Bae Kim University of Ulsan
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Woo Kyung Moon
Woo Kyung Moon Seoul National University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens the door to a wide spectrum of related healthcare degrees and career pathways you can pursue online. These programs are ideal for those seeking flexibility, career advancement, or a transition into medical fields.

If you're interested in leadership roles within healthcare, healthcare administration programs can provide the management skills required to oversee hospitals and clinics. Similarly, for those aiming for executive positions, consider online mha programs cahme accredited, which are recognized for their industry-standard curricula and accreditation.

Nursing professionals who want to advance can benefit from bridge programs. The adn to fnp programs offer a fast track from an associate’s degree to becoming a family nurse practitioner, opening new clinical and leadership opportunities.

If you’re passionate about preventative health and dietary sciences, an online bachelor's degree in nutrition provides the foundation needed to impact community health as a qualified nutritionist or wellness coach.

Each pathway supports vital roles within healthcare and can be tailored to suit diverse interests and schedules, helping you take the next step in your medical or allied health career.

Best Scientists Citing Seock-Ah Im

Trending Scientists

Recently Published Articles